Surgery or Chemoradiotherapy for Cervical Esophageal Cancer

Surgery Versus Definitive Chemoradiotherapy for Resectable Cervical Esophageal Squamous Cell Carcinoma: A Prospective Multicenter Open-Label Clinical Trial

To compare surgery with definitive chemoradiotherapy for patients with resectable cervical esophageal squamous cell carcinoma.

Inclusion Criteria:

• Patients with resectable cervical esophageal squamous cell carcinoma (cT1b-T4aN0-3M0);
• Cervical esophageal cancers spreads upwards to involve the hypopharynx and downwards to involve the thoracic esophagus can also be included;
• Aged 18-75 years;
• Without any contraindication of operation;
• Hemoglobin >=90 g/L; Leukocytes >=4.0x10^9/L; Absolute neutrophil count >=1.5x10^9/L; Platelet >=100x10^9/L;Total bilirubin <=1.5 ULN; ALT <=2.5 ULN; AST <=2.5 ULN; Serum creatinine <=1.5 ULN or creatinine clearance rate >=50 mL/min (Cocheroft-Gault);INR <=1.5 ULN; APTT <=1.5 ULN;
• Without other malignancies;
• Expected R0 resection;
• ECOG PS 0-1;
• Volunteered to participate in the study, signed the informed consent form.

Exclusion Criteria:

• Without other malignancies;
• With mental diseases;
• With hemorrhagic disease;
• Inoperable patients;
• Pregnant or lactating women;
• Has a history of allergy to paclitaxel or cisplatin